

AMYRIS BRANDS EXPANDING IN UK AND EUROPE. EXECUTING ON CONTINUED ACCELERATED GROWTH AND LOWER COSTS

EMERYVILLE, Calif., Oct. 11, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that three of its consumer brands will be included in [Sephora's launch in the United Kingdom \(UK\)](#).

When Sephora launches its UK website on October 17th, three Amyris brands – Biossance, JVN Hair and Rose Inc – will be available on Sephora UK's website. In addition, Biossance and JVN will be available at the flagship brick and mortar store in London, opening March 2023.

This expansion of Amyris' brands in the UK is the latest step in its global partnership with Sephora and further evidence of Amyris' growth around the globe. Amyris was recently recognized by Women's Wear Daily (WWD) as the leading small cap beauty company in the world due to its execution on what consumers are seeking in clean, sustainable products that deliver best-in-class performance.

Today, consumers in the UK already enjoy access to Amyris consumer brands sold in SpaceNK, Selfridges, Harrods, Cult Beauty, and will also be able to access Amyris' brands via their direct-to-consumer brand websites in the coming months. Amyris plans to expand its offering in the UK and Europe with additional brands and retail store presence during 2023.

"Amyris consumer brands are delivering some of the best performance in health and beauty and are accelerating on the back of significant consumer demand across the critical global markets for clean, sustainable health and beauty products at an accessible price," said John Melo, President and Chief Executive Officer. "We are executing very well, and our revenue has continued to grow sequentially. Consumers are doubling down on clean beauty. Along with some of the strongest growth across the beauty industry for our ingredients and consumer business, we are making great progress on lowering our costs with "Fit to Win," designed to deliver operational excellence. We are pleased with the closing of our short-term financing that we announced this morning and are set for an excellent finish to 2022."

About Amyris

Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit <http://www.amyris.com>.

Amyris, the Amyris logo, and Lab-to-Market, are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris' inclusion in Sephora's UK launch; and Amyris' expectations about the expansion of its brands in the UK, the acceleration of consumer revenue and lowering of operating costs, and performance for the remainder of the year 2022. These statements are based on management's current expectations and actual results and future events may differ materially due

to risks and uncertainties, including risks related to Amyris' liquidity and ability to fund operating and capital expenses, risks related to its financing activities, risks related to potential delays or failures in completing and integrating planned acquisitions, risks related to potential delays or failures in development, regulatory approval, launch, production and commercialization of products, risks related to the COVID-19 pandemic and any other geopolitical events, including Russia's invasion of Ukraine, resulting in global economic, financial and supply chain disruptions that may negatively impact Amyris' business operations and financial results or cause market volatility, risks related to Amyris' reliance on third parties particularly in the supply chain, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

SOURCE Amyris, Inc.

For further information: For further information: Investors: Amyris, Inc., Paul Vincent, vincent@amyris.com, +1 (510) 450-0761, Argot Partners, Jason Finkelstein, amyris@argotpartners.com, +1 (212) 600-1902, Media: Amyris, Inc., Beth Bannerman, bannerman@amyris.com, +1 (510) 914-0022

<https://investors.amyris.com/2022-10-11-Amyris-Brands-Expanding-in-UK-and-Europe-Executing-on-continued-accelerated-growth-and-lower-costs>